[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100332134":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":67,"centralContacts":71,"locations":78,"responsibleParty":97,"collaborators":99,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":76,"eligibilityCriteria":109,"healthyVolunteers":105,"sex":110,"minAge":111,"maxAge":76,"enrollmentInfo":112,"targetDuration":76,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":76,"overallStatus":81,"whyStopped":76,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment (FDG PET\u002FCT, [18F]FTT PET\u002FCT)","EXPERIMENTAL","Patients receive FDG IV and undergo FDG PET\u002FCT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo \\[18F\\]FTT PET\u002FCT over 1 hour.",[13,14,15,16],"Procedure: Computed Tomography","Radiation: Fludeoxyglucose F-18","Radiation: Fluorine F 18 Fluorthanatrace","Procedure: Positron Emission Tomography",[18,31,35,48,54,64],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Computed Tomography","Undergo FDG PET\u002FCT",[9],[24,25,26,27,28,29,30],"CAT","CAT Scan","Computerized Axial Tomography","computerized tomography","CT","CT SCAN","tomography",{"type":19,"name":20,"description":32,"armGroupLabels":33,"otherNames":34},"Undergo \\[18F\\]FTT PET\u002FCT",[9],[24,25,26,27,28,29,30],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"RADIATION","Fludeoxyglucose F-18","Given IV",[9],[41,42,43,44,45,46,47],"18FDG","FDG","Fludeoxyglucose (18F)","fludeoxyglucose F 18","Fludeoxyglucose F18","Fluorine-18 2-Fluoro-2-deoxy-D-Glucose","Fluorodeoxyglucose F18",{"type":36,"name":49,"description":38,"armGroupLabels":50,"otherNames":51},"Fluorine F 18 Fluorthanatrace",[9],[52,53],"[18F]FluorThanatrace","[18F]FTT",{"type":19,"name":55,"description":21,"armGroupLabels":56,"otherNames":57},"Positron Emission Tomography",[9],[58,59,60,61,62,63],"Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging",{"type":19,"name":55,"description":32,"armGroupLabels":65,"otherNames":66},[9],[58,59,60,61,62,63],[68],{"name":69,"affiliation":5,"role":70},"Lilie L Lin","PRINCIPAL_INVESTIGATOR",[72],{"name":73,"role":74,"phone":75,"phoneExt":76,"email":77},"Lilie Lin","CONTACT","713-563-2300",null,"lllin@mdanderson.org",[79],{"facility":80,"status":81,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":88,"coordinates":89},"Point",[90,91],-95.36327,29.76328,{"lat":91,"lon":90},[94,96],{"name":95,"role":74,"phone":75,"phoneExt":76,"email":77},"Lilie L. Lin, MD",{"name":95,"role":70,"phone":76,"phoneExt":76,"email":76},{"type":98,"investigatorFullName":76,"investigatorTitle":76,"investigatorAffiliation":76,"oldNameTitle":76,"oldOrganization":76},"SPONSOR",[100],{"name":101,"class":102},"National Cancer Institute (NCI)","NIH","100332134","phase-1-serial-imaging-of-the-novel-radiotracer-18f-fluorthanatrace-18f-ftt-by-petctf-100332134",false,"NCT03604315","Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET\u002FCTF","Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET\u002FCT","Inclusion Criteria:\n\n* History of known or suspected solid tumor.\n* At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\], ultrasound, fludeoxyglucose \\[FDG\\] PET\u002FCT).\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \\\u003C 2 weeks prior to screening as standard of care.\n* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n* Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.","FEMALE","18 Years",{"count":113,"type":114},300,"ESTIMATED","INTERVENTIONAL",[117],"PHASE1","This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)\u002Fcomputed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET\u002FCT uses a scanner to make detailed, computerized pictures of areas inside the body. PET\u002FCT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.",[120,121,122,123,124,125,126,127],"Breast Carcinoma","Fallopian Tube Carcinoma","Ovarian Carcinoma","Primary Peritoneal Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Solid Neoplasm","2026-04-10",{"date":130,"type":131},"2026-04-15","ACTUAL",{"date":133,"type":131},"2018-12-18",{"date":135,"type":114},"2027-06-30",{"name":5,"class":6},1]